Summit hits unforeseen possible lung cancer snag

Also: Biotech veteran Harvey Berge's new endeavor to develop a new kind of research institute focusing on cancer

September 9, 2025 Check out STAT+

Sponsored By

Adobe STAT+ | Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster The drug, ivonescimab, produced weaker results in patients from North America and Europe than those from China. By Adam Feuerstein STAT+ | Biotech veteran Harvey Berger takes over as CEO of billionaire-backed Arena Bioworks The research institute, which has said it has taken inspiration from the storied Bell Labs, has been experiencing a period of transition. By Allison DeAngelis A promising new treatment for a tough cancer Today's health news covers a promising new treatment for a tough cancer, Florida vs. Trump vs. RFK Jr. vaccine requirements, etc. By Theresa Gaffney 10 times STAT coverage reverberated through health and medicine As STAT turns 10, a look at our milestone stories: Purdue Pharma secrets, UnitedHealth denials, hepatitis in prisons, Covid pandemic coverage, and more. By STAT Staff

More around STAT

---

In case you missed it Astrazeneca's lung cancer combination boosted survival in key study, Bloomberg Eli Lilly's blood cancer drug shows promise in trial as early treatment, Reuters He started fighting wildfires as a teenager. After inhaling smoke on the front lines for six seasons, he faced an impossible choice, New York Times

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser